Polyrizon announces publication of u.s. national patent application for its innovative hydrogel nasal technologies

Raanana, israel, dec. 30, 2024 (globe newswire) -- polyrizon ltd. (nasdaq: plrz) (the "company" or "polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of a national phase patent application by the united states patent and trademark office (“uspto”). the patent application encompasses key aspects of polyrizon's two core platform technologies: capture and contain (c&c™), a nasal blocker technology, and trap and target (t&t™), designed for advanced nasal drug delivery. both technologies represent polyrizon's commitment to creating innovative solutions for protecting and treating via the nasal cavity.
PLRZ Ratings Summary
PLRZ Quant Ranking